c67a8cd34d908c189.0M-bSv0S9_OBnryx-hFgYvE5UUjjtzUKNZV0UHLNwMU.mYnwIMpVz6Hj54rbyEE1FIRSDh2b7mRkYPgrMRWHo7WYje8wyl6Otemr9Q
24-01-31 Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index CI
24-01-26 Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index CI
24-01-17 Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market MT
24-01-17 Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer CI
24-01-17 Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer CI
24-01-17 Aravive, Inc. Announces Board and Committee Resignations CI
24-01-17 Aravive, Inc. to Delist from The Nasdaq Stock Market AQ
23-11-09 Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-08-22 Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18 MT
23-08-21 Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
23-08-03 Top Midday Decliners MT
23-08-03 EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10 MT
23-08-03 HC Wainwright Downgrades Aravive to Neutral From Buy MT
23-08-03 William Blair Downgrades Aravive to Market Perform From Outperform MT
23-08-03 BTIG Downgrades Aravive to Neutral From Buy MT
23-08-02 Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer AQ
23-08-02 Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer CI
23-07-28 Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023 AQ
23-07-14 Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023 AQ
23-07-10 BTIG Adjusts Price Target on Aravive to $9 From $12, Maintains Buy Rating MT
23-06-23 Aravive, Inc.(NasdaqGS:ARAV) added to Russell 3000E Growth Index CI
23-06-23 Aravive, Inc.(NasdaqGS:ARAV) added to Russell Microcap Growth Index CI
23-06-13 Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c) AQ
23-06-05 ARAVIVE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
23-06-05 Aravive To Participate in the Jefferies Global Healthcare Conference AQ

Become a member to access more news

New member
No results match your criteria